NLRP3 and Alzheimer disease: In summary, therapeutic strategies aimed at reducing ROS—whether by enhancing Nrf2 activity, employing mitochondria targeted antioxidants such as MitoQ and SS-31, inhibiting the NLRP3 inflammasome via agents including MCC950 or SB_NI_112, or using caspase inhibitors such as VX-765—represent promising approaches to mitigating the neurodegenerative processes associated with both AUD and AD.